DNA vaccine for TB prevents recurrence

Bowden, Rachel
February 2005
GP: General Practitioner;2/11/2005, p4
This article informs that a DNA vaccine for TB prevents recurrence of the disease in mice. Researchers infected four groups of mice with a low dose of Mycobacterium tuberculosis and treated them with the anti-tubercular agents isoniazid and pyrazinamide five times in the first four to 16 weeks after infection. Three groups were also given a DNA vaccine for TB. The first group's contained the M tuberculosis gene Ag85A, the second group's contained the PstS-3 gene and the third group's contained both.


Related Articles

  • Another Step Down the Development Pipeline for the Novel Tuberculosis Vaccine MVA-85A. Dockrell, Hazel M. // Journal of Infectious Diseases;6/15/2011, Vol. 203 Issue 12, p1708 

    In this article the author discusses development of the novel tuberculosis vaccine MVA-85A. The author says that infants had lower enzyme-linked immunosorbent spot (ELISPOT) responses to MVA85A than children aged 2-5 years, adolescents, or adults. The author further says that there were several...

  • Government told to set clearer TB action targets.  // Nursing Standard;2/9/2005, Vol. 19 Issue 22, p6 

    Focuses on specific targets needed to ensure the British government's action plan on tuberculosis (TB). Reason for the limitation of the plan; Scope of the action plan; Importance of controlling the spread of the disease.

  • Progression to Active Tuberculosis, but Not Transmission, Varies by Mycobacterium tuberculosis Lineage in The Gambia. de Jong, Bouke C.; Hill, Philip C.; Aiken, Alex; Awine, Timothy; Antonio, Martin; Adetifa, Ifedayo M.; Jackson-Sillah, Dolly J.; Fox, Annette; DeRiemer, Kathryn; Gagneux, Sebastien; Borgdorff, Martien W.; McAdam, Keith P. W. J.; Corrah, Tumani; Small, Peter M.; Adegbola, Richard A. // Journal of Infectious Diseases;10/1/2008, Vol. 198 Issue 7, p1037 

    Background. There is considerable variability in the outcome of Mycobacterium tuberculosis infection. We hypothesized that Mycobacterium africanum was less likely than M. tuberculosis to transmit and progress to tuberculosis disease. Methods. In a cohort study of patients with tuberculosis and...

  • Combined DNA Vaccines Formulated in DDA Enhance Protective Immunity against Tuberculosis. Cai, H.; Tian, X.; Hu, X. D.; Zhuang, Y. H.; Zhu, Y. X. // DNA & Cell Biology;Jul2004, Vol. 23 Issue 7, p450 

    This study evaluated the adjuvant Dimethyldioctyldecyl Ammonium Bromide (DDA) effect on the protective immunity induced by a combination of plasmids containing genes encoding antigens Ag85B, MPT-83, and ESAT-6 from Mycobacterium tuberculosis. The combined DNA vaccines in DDA resulted in...

  • Natural Variation in Immune Responses to Neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian Infants. Finan, Chris; Ota, Martin O. C.; Marchant, Arnaud; Newport, Melanie J. // PLoS ONE;2008, Vol. 3 Issue 10, p1 

    Background: There is a need for new vaccines for tuberculosis (TB) that protect against adult pulmonary disease in regions where BCG is not effective. However, BCG could remain integral to TB control programmes because neonatal BCG protects against disseminated forms of childhood TB and many new...

  • PhoP: A Missing Piece in the Intricate Puzzle of Mycobacterium tuberculosis Virulence. Gonzalo-Asensio, Jesús; Mostowy, Serge; Harders-Westerveen, Jose; Huygen, Kris; Hernández-Pando, Rogelio; Thole, Jelle; Behr, Marcel; Gicquel, Brigitte; Martín, Carlos // PLoS ONE;2008, Vol. 3 Issue 10, p1 

    Inactivation of the transcriptional regulator PhoP results in Mycobacterium tuberculosis attenuation. Preclinical testing has shown that attenuated M. tuberculosis phoP mutants hold promise as safe and effective live vaccine candidates. We focused this study to decipher the virulence networks...

  • UNA NUEVA GENERACIÓN DE VACUNAS ANTITUBERCULOSAS. J. Brennan, Michael // Vacunas: Prevención de enfermedades y protección de la salud;2004, p193 

    The article presents information on the development of effective vaccines for tuberculosis in the developing world. The need to develop vaccines for malaria and AIDS is one of the biggest challenges presently. It has been found that approximately 2 million HIV-negative individuals die because of...

  • High Incidence of Tuberculosis among HIV-Infected Infants: Evidence from a South African Population- Based Study Highlights the Need for Improved Tuberculosis Control Strategies. Hesseling, A. C.; Cotton, M. F.; Jennings, T.; Whitelaw, A.; Johnson, L. F.; Eley, B.; Roux, P.; Godfrey-Faussett, P.; H. S. Schaaf // Clinical Infectious Diseases;1/1/2009, Vol. 48 Issue 1, p108 

    Background. There are limited population-based estimates of tuberculosis incidence among human immunodeficiency virus (HIV)-infected and HIV-uninfected infants aged 12 months. We aimed to estimate the population-based incidence of culture-confirmed tuberculosis among HIV-infected and...

  • Diagnosis of latent tuberculosis infection in healthy young adults in a country with high tuberculosis burden and BCG vaccination at birth. Dagnew, Alemnew F.; Hussein, Jemal; Abebe, Markos; Zewdie, Martha; Mihret, Adane; Bedru, Ahmed; Chanyalew, Menberework; Yamuah, Lawrence; Medhin, Girmay; Bang, Peter; Doherty, T. Mark; Hailu, Asrat; Aseffa, Abraham // BMC Research Notes;2012, Vol. 5 Issue 1, p415 

    Background: One third of the world's population is thought to have latent tuberculosis infection (LTBI) with the potential for subsequent reactivation of disease. To better characterize this important population, studies comparing Tuberculin Skin Test (TST) and the new interferon-γ release...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics